CME-Certified Practice Patient Visit Case Challenge

Release Date:    Sunday, November 2, 2014
Expiration Date:    Sunday, November 1, 2015
Estimated Time To Complete Activity:    30 minutes

To participate in this activity, please click on the ‘launch’ button. You will be redirected to RealCME.com where you will be asked to sign in.

This CME-accredited activity, Worldwide Views On SGLT2 Inhibitors To Optimize Glucose Homeostasis In Type 2 Diabetes Mellitus: An Interactive Patient Case Study, developed by Anne Peters, MD, is an on-demand interactive case challenge providing 0.5 AMA PRA Category 1 Credit(s)™ utilizing The PracticePatient Visit format on the RealCME technology platform with outcomes integration. The case-based simulation design will allow participants to demonstrate learning by integrating authentic decision-making opportunities, peer-to-peer interactions, and expert inter-professional discussions that are consistent with day-to-day patient care pertaining to the treatment management of patients with type 2 diabetes.

Faculty
Anne L. Peters, MD

Keck School of Medicine
University of Southern California

Target Audience
This activity is intended for meeting the educational needs of clinical endocrinologists, endocrine fellows, primary care physicians, endocrine nurses, scientists and other healthcare professionals who manage the care of patients with type 2 diabetes mellitus.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Review the role of the kidney in blood glucose regulation in type 2 diabetes mellitus
  • Validate the rationale for SGLT2 inhibitor therapy based on its unique glycosuria-based mechanism of action
  • Determine the appropriate use of SGLT2 therapy in patients with type 2 diabetes that are otherwise healthy or exhibit higher blood glucose concentration
  • Integrate emerging evidence on novel SGLT2 inhibitors into the treatment paradigm for patients with type 2 diabetes mellitus


Accreditation Statement
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

Credit Designation
Endocrine Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: 

Anne L. Peters, MD, CDE, reported a financial interest/relationship or affiliation in the form of: Consultant: Ad Hoc, Abbott Laboratories; Speaker, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Novo Nordisk; Advisory Board , Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic Minimed, sanofi US.

The following Special Program Committee members who planned and/or reviewed content for this activity reported relevant financial relationships: 

Endocrine Society staff associated with the development of this program reported no relevant financial relationship and/or conflicts of interest.

AXIS Medical Education staff associated with the development of this program reported no relevant financial relationship and/or conflicts of interest: Linda King, MS; Deb Middleton, MS; and Diedrea White, BA.

Policy on Unlabeled/Off-Labeled Use
Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.

Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Acknowledgement of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.